Wave Life Sciences advances WVE-007 to Phase 2a for obesity, targeting BMI 35–50 with comprehensive endpoints including body composition...

FDA approves Pluvicto for metastatic hormone-sensitive prostate cancer, reducing progression or death risk by 33% when added to standard...

JAMA's deescalation trial framework forces a reckoning: 22% of prescriptions are unnecessary, and regulators have no standard playbook for...

Co-Diagnostics raises capital through warrant inducement agreement while awaiting FDA clearance for its first diagnostic platform.

Nature Medicine finds neuroimaging AI trained on routine health system data beats curated trial datasets. FDA's RWE framework for...

Keros receives $20M milestone as elritercept Phase 3 trial enrolls first patient in MDS study with demanding transfusion independence...

FibroBiologics doses first patients in CYWC628 Phase 1/2 trial for diabetic foot ulcers, targeting interim data by year-end 2026.

Moleculin Biotech updates Annamycin data from its MIRACLE trial in relapsed AML, pricing stock offering at $0.75 per share.

Karyopharm's selinexor misses primary endpoint in Phase 3 endometrial cancer trial despite showing 5.32-month PFS improvement over placebo.

Latigo Biotherapeutics' LTG-001 hit SPID48 in 343 patients, published in NEJM — here's what the trial design tells regulators...